Piramal Pharma Ltd

Piramal Pharma Ltd has announced the successful closure of the US FDA inspection at its manufacturing facility located in Sellersville, USA. This follows a prior intimation on May 10th, 2026, regarding the inspection. The US FDA has issued an Establishment Inspection Report (EIR), confirming the successful closure of the inspection. This development is positive for the company's regulatory standing and operational compliance in the United States.

Piramal Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, along with an Independent Auditor’s Limited Assurance Report from DNV Business Assurance India Pvt Ltd. The report details the company's corporate identity, registered and corporate office addresses, financial year of reporting (April 1, 2025, to March 31, 2026), and stock exchange listings (NSE and BSE). It covers business activities contributing 100% to turnover, primarily pharmaceuticals manufacturing. The company operates 91 plants and 33 offices nationally, and 7 plants and 19 offices internationally, serving over 100 countries. Exports constitute 72.78% of total turnover. The report also includes employee data, with a total of 6,774 employees and 3,666 workers, and highlights the participation of women in leadership roles, with 30% on the Board of Directors and 50% in Key Management Personnel.

Piramal Pharma Ltd has issued a notice for its 6th Annual General Meeting (AGM) scheduled for July 30, 2026, at 3:00 p.m. IST, to be conducted via Video Conferencing/Other Audio Visual Means. The company has also released its Annual Report for the financial year 2025-26, which includes the Business Responsibility & Sustainability Report. The report details the company's performance highlights, leadership message, sustainability efforts, macroeconomic and industry overviews, business-wise performance, financial review, and management discussion and analysis. The Annual Report and AGM notice are being sent electronically to members with registered email addresses and physically to others via a weblink and QR code. The documents are also available on the company's website.

Piramal Pharma Ltd has announced its 6th Annual General Meeting (AGM) scheduled for July 30, 2026, at 3:00 p.m. IST, to be conducted via Video Conferencing/Other Audio Visual Means. The company has also released its Annual Report for the financial year 2025-26, which includes the Business Responsibility & Sustainability Report. The report details the company's performance highlights, leadership message, sustainability efforts, macroeconomic and industry overviews, business-wise performance, financial review, and management discussion and analysis. The Annual Report and AGM Notice are being sent electronically to members with registered email addresses and physically to others, and are also available on the company's website.

Piramal Pharma Limited has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in effect from Wednesday, July 1, 2026, and will remain shut until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The specific date for the Board Meeting to approve these financial results will be communicated later. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Piramal Pharma Ltd has responded to a stock exchange query regarding a news article that reported a significant surge in its share price. The company clarified that the referenced article does not contain any new material information requiring disclosure under SEBI regulations. Piramal Pharma stated that all previously disclosed information is in the public domain and there are no undisclosed material events. The company attributes the recent share price movement to market dynamics and is not aware of any specific reason for the observed rally.

Piramal Pharma Limited has received an order from the Gujarat Pollution Control Board (GPCB) granting a permanent revocation of the closure directions issued under Section 33A of the Water Act for its Dahej plant. This follows previous interim revocations. The company confirms that operations at the Dahej site are proceeding normally and reiterates its commitment to environmental compliance. This development removes a significant operational risk for the company's manufacturing facility in Gujarat.

Piramal Pharma Ltd. announced that the US FDA has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Digwal, Telangana, India. This signifies the successful closure of the US FDA inspection at the facility. The company is submitting this information following the receipt of the EIR.

Piramal Pharma Ltd has provided the contact details of its Key Managerial Personnel (KMP) in compliance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosed KMPs are Mr. Vivek Valsaraj, Chief Financial Officer, and Mr. Maneesh Sharma, Company Secretary and Compliance Officer. These details are for determining the materiality of events and for making necessary disclosures to the stock exchanges.

Piramal Pharma's Board of Directors, at its meeting on April 28, 2026, approved the Audited Financial Statements and Results (Standalone & Consolidated) for the quarter and financial year ended March 31, 2026. The Board also approved the re-appointment of four key directors, subject to shareholder approval. Ms. Nandini Piramal was re-appointed as Whole-Time Director, Executive Director, and Chairperson for three years from April 1, 2027. Mr. Peter DeYoung was re-appointed as Whole-Time Director and Executive Director for three years from October 6, 2026. Mr. Sridhar Gorthi and Mr. Peter Stevenson were both re-appointed as Non-Executive, Independent Directors for a second term of five years from March 30, 2027, with Mr. Stevenson continuing post 75 years of age.